Welcome to our dedicated page for Endo news (Ticker: NDOI), a resource for investors and traders seeking the latest updates and insights on Endo stock.
Endo, Inc. (OTCQX: NDOI) is a diversified specialty pharmaceutical company whose news flow spans product launches, clinical research updates, financial results and major corporate transactions. As a participant in the Drug Manufacturers – Specialty & Generic industry, Endo issues frequent press releases on branded therapies, sterile injectables, generics and strategic initiatives.
Investors and healthcare professionals following NDOI news can see updates on clinical development programs, such as Phase 1, Phase 2 and Phase 3 studies of collagenase clostridium histolyticum in plantar fibromatosis and plantar fasciitis, as well as retrospective analyses of patient experiences. Endo also reports on educational initiatives like its Spatial Computing Injection Simulator for Peyronie’s disease, which supports appropriate use of XIAFLEX, the only FDA‑approved nonsurgical treatment for that condition.
Endo’s news feed also features product and portfolio announcements, including expansions of its ADRENALIN epinephrine premixed IV bag line within the Endo Injectable Solutions TruDelivery platform. These releases often include detailed prescribing and safety information relevant to hospital pharmacists and clinicians.
From a capital markets perspective, NDOI news includes quarterly financial results, segment performance commentary across Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals, and reaffirmations or updates to financial guidance. In addition, Endo provides regular updates on its proposed combination with Mallinckrodt plc, shareholder approvals, court rulings and the planned separation of the combined generics and sterile injectables business into an entity intended to be called Par Health.
This page aggregates these company‑issued updates so readers can review Endo’s latest disclosures on products, pipelines, financial performance and corporate transactions in one place.
Endo (OTCQX: NDOI) announced three presentations at the American Podiatric Medical Association Annual Meeting from July 24-27, 2025, focusing on plantar fibromatosis (PFI) and plantar fasciitis (PFA) research. The presentations include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum (CCH) and a retrospective patient analysis.
The company is currently advancing a Phase 3 study investigating CCH as a potential nonsurgical treatment for PFI patients. The research presentations cover clinical trial data, patient experiences, and dose escalation studies, demonstrating Endo's commitment to developing treatments for challenging conditions.
Endo (OTCQX: NDOI) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before the market opens. The company will host a conference call at 8:00 a.m. ET on the same day.
Investors can access the audio webcast through the company's Investor Relations website at investor.endo.com. For those preferring a conference line, dial-in numbers are provided: 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (international). Participants should join 10 minutes before the start time. A webcast replay will be available after the event.
Mallinckrodt plc has secured a crucial ruling from the Irish High Court for its planned merger with Endo, Inc. (OTCQX: NDOI). This represents the final major legal hurdle for the stock and cash transaction, which is expected to close in early August 2025.
The merger, initially announced on March 13, 2025, aims to create a global therapeutics leader. Both companies' shareholders approved the deal last month. The combined entity will be headquartered in Dublin, Ireland, with Siggi Olafsson serving as President and CEO.
Post-merger, the companies plan to combine their generic pharmaceuticals and Endo's sterile injectables businesses, with a future intention to separate these operations from the combined company, subject to board approval.
Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.
The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.